AC Immune S.A. (ACIU) vs X4 Pharmaceuticals, Inc. (XFOR)
A side-by-side comparison of AC Immune S.A. and X4 Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACIU
AC Immune S.A.
$2.53HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
XFOR
X4 Pharmaceuticals, Inc.
$2.77HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — ACIU vs XFOR
growth of $100 · dividends reinvested · last 9yACIU -75.0% (-14.3%/yr)XFOR -99.9% (-52.9%/yr)ACIU compounded faster over this window
Log scale — wide-divergence pair
ACIU XFOR
ACIU vs XFOR: by the numbers
- •XFOR is the larger company ($261M vs $257M market cap).
- •Both run net losses; ACIU's is the smaller (-249.94% vs -568.80% net margin).
Metrics side by side
Valuation
| Metric | ACIU | XFOR |
|---|---|---|
| P/S ratio | 11.86 | 16.46 |
| P/B ratio | 5.92 | 1.68 |
Profitability
| Metric | ACIU | XFOR |
|---|---|---|
| Gross margin | 100.00% | 81.22% |
| Operating margin | -1927.32% | -247.44% |
| Net margin | -249.94% | -568.80% |
| ROE | -124.67% | -57.98% |
| ROIC | -89.43% | -37.61% |
Growth (annualized)
| Metric | ACIU | XFOR |
|---|---|---|
| Revenue CAGR (5Y) | -23.70% | N/A |
| Total return CAGR (5Y) | -16.03% | -55.06% |
Frequently asked
- How have ACIU and XFOR total returns compared?
- Over the past 5 years, ACIU delivered -16.03% and XFOR delivered -55.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.